FoxScore

Analysis for Jiangsu Hengrui Medicine

Description & usage

Jiangsu Hengrui Medicine develops innovative and generic pharmaceuticals, with strong exposure to oncology and specialty therapies. The company benefits from intensive R&D and broad domestic market presence in China. Key valuation drivers are pipeline progress, approvals, product mix, and margin trends.

Basic info

Symbol
600276.SS
Type
Stock
Region
Asia
Sector
Health Care
Available history
11.2 years
Last trading day
04/03/2026

Market context

DXY
120.89
US 10Y Real
1.99%
Fed Balance
$6.68T
CPI YoY
2.4%
Fed Rate
3.75%
US 10Y
4.35%
VIX
24.54
HY OAS
3.17%
Brent
$121.88
Core CPI
2.5%
US 2Y
3.84%
ISM PMI

Score overview

The overall score combines Performance, Stability and Trend into one comparable value.

Analysis summary

Technical picture

Overall, the picture looks calm but not clearly directional. Performance is currently doing more of the work than stability, with sub-scores of 49 for performance, 33 for stability and 39 for trend. Short- and long-horizon evidence are closer together, so no single timeframe fully dominates the read.

The strongest support currently comes from the more recent return profile. One- and three-year returns are running at 20.9 % and 24.7 %, which gives the setup some current traction.

The main drag is the lack of clear direction. Trend strength is only -0.8, which means the chart is not broken, but it also is not decisive enough for a stronger trend call.

The next important change would be clearer direction. Right now the chart is neither broken nor convincing enough to support a stronger technical call.

Current market backdrop

The backdrop is improving on inflation, but not yet on financing conditions. Price pressure is cooling, yet rates still remain high enough to matter.

US 10-year yields remain elevated at 4.35%.

Inflation is cooling, with headline and core readings around 2.4% and 2.5%.

US inflation-adjusted 10-year yields are still high at 1.99%.

In plain language, the inflation trend is moving in a better direction, but financing conditions are not easy yet. That often means the macro picture improves faster than policy relief arrives.

The ISM business activity gauge are currently unavailable or too stale to use, so this is a narrower macro read than usual.

What that means for this asset

For stocks, broad risk appetite matters because it shapes how willing investors are to pay for cyclical exposure or future growth expectations.

At the moment, the environment is demanding enough that a merely okay chart is not enough. The setup needs more proof than it would in an easier backdrop.

In plain terms, this looks usable, but selective rather than fully clear-cut. The chart does part of the work, yet the backdrop still sets limits around how strong the reading should be.

Historical evaluation and qualitative market context only, not investment advice.

Price chart

Use the chart to read recent price behavior before drilling into metrics.

Show chart
If you continue, the chart will be loaded from TradingView. Technical data such as your IP address may be transferred to TradingView.

Explore rankings

Open the ranking view you need.

  1. Asset types

    Open rankings by asset type.

  2. Scores

    Open the four score rankings directly and see how the scores are explained.

  3. Metrics

    Open rankings by individual metrics and see what each metric means.

  4. Countries

    Open country rankings and compare how markets perform.

Data snapshot

Validated
Snapshot as of
Apr 03, 2026
Last trading day
Apr 03, 2026
Snapshot status
Validated
Data quality
Passed

Freshness, data quality, and exclusions stay visible. Unavailable values and insufficient history are never treated as valid data.